Jul 14, 2020 — 5 min read
The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others.
“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said CB Insights CEO Anand Sanwal. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year's class of the best in digital health."
“We are honored to be named as one of the most innovative digital health companies by CB Insights for two consecutive years,” said Lunit CEO Brandon Suh. “We are actively collaborating with global giants such as FujiFilm and GE Healthcare to provide our solution for precision diagnostics and therapeutics. Continuous recognition of our AI solution in Screening & diagnostics shall boost our footprint to set the new standard of healthcare.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.
Lunit develops AI software to solve some of the most important problems today in cancer diagnosis and treatment. Lunit’s solution for imaging tests such as mammography and chest x-ray provide AI-powered detection of lesions that are suspicious of chest abnormalities and breast cancer with 96-99% accuracy. The software has received CE mark and has been featured in major publications including Radiology, Lancet Digital Health, JAMA Network Open, Clinical Infectious Diseases, and more.
The 2020 Digital Health 150 startups have raised over $20B in funding across 600+ deals from 900+ unique investors.
The list includes 12 unicorns (companies that have reached a valuation of $1B+) focused on a diverse range of digital health solutions, including telehealth, insurance, and robotic surgical systems.
Many have formed partnerships with key industry players like the American Heart Association, Cigna, and Mount Sinai Health System.
98Point6, Abacus Insights, AbCellera Biologics, Aetion, Akili Interactive Labs, Alan, Aledade, Alpha Health, Arterys, Atomwise, Avail Medsystems, Axial Healthcare, Babyscripts, Bend Financial, Bigfoot Biomedical, Bind Benefits, Biofourmis, Biointellisense, Bright Health, Bright.MD, BrightInsight, Brightside Benefit, Cala Health, Capsule, Caption Health, Carbon Health, Carrot Fertility, Cedar, Celsius Therapeutics, ChromaCode, Cityblock Health, CMR Surgical, Concerto HealthAI, Cricket Health, Cue Health, CureApp, Current Health, Dental Monitoring, Devoted Health, DispatchHealth, DNAnexus, Doctolib, Doctor On Demand, Dreem, Eko, Element Science, Evidation Health, Firefly Health, Folx Health, Freenome, Galileo Health, Genome Medical, GRAIL, GYANT, HaloDoc, Happify Health, Healthy.io, Healx, Heartbeat, Hims & Hers, Hinge Health, icometrix, iLoF, Incredible Health, Infervision, Innovaccer, Insilico Medicine, Insitro, Iora Health, K Health, Kaia Health, Karius, Kindbody, Komodo Health, League, LeanTaaS, LetsGetChecked, Livi, Lunit, Lyra Health, Mahmee, Mammoth Biosciences, Maven Clinic, Medable, Medbanks Network Technology, Medically Home Group, MediTrust Health, Meru Health, Mindbloom, Mindstrong, Modern Fertility, Mojo Vision, mPharma, nference, Notable, Nuvo Group, Olive, Omada Health, Oncology Analytics, Onera Health, Oscar Health, Oura, OWKIN, PAIGE.AI, Parsley Health, PathAI, Pear Therapeutics, Perspectum, PharmEasy, ProteinQure, Protenus, Quartet Health, Qure.ai, RDMD, Ready Responders, Recursion Pharmaceuticals, Redox, Ro, Saama Technologies, Science 37, Sema4, Somatus, SonarMD, SOPHiA Genetics, Subtle Medical, Taimei Technology, Tempus, Tencent Trusted Doctors, Thrive Earlier Detection, TriNetX, Truepill, Twistle, TytoCare, Unite Us, Unlearn, Valencell, Verana Health, Vesta Healthcare, Vicarious Surgical, VillageMD, Vim, Vineti, Virta Health, Viz.ai, We Doctor, Wellth, Winterlight Labs, Xealth, XtalPi, Zebra Medical Vision
At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.
With AI, Lunit aims to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide. We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.
Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images. Our technology has been recognized at international competitions such as ImageNet (5th place, 2015), TUPAC 2016 (1st place), and Camelyon 2017 (1st place), surpassing top companies like Google, IBM, and Microsoft. Lunit is headquartered in Seoul, South Korea with offices and representatives in the U.S.A., Netherlands, and China.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021